SlideShare ist ein Scribd-Unternehmen logo
1 von 31
Heparin-Induced Thrombocytopenia: A Case Presentation Darcie Gampetro Pharm.D Candidate 2011 September 2010
Patient JB ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patient JB ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
JB Past Medical History ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Home Medications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Inpatient Medications Day 1 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Day 2 Medication Changes ,[object Object],[object Object],[object Object],[object Object]
Day 4 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Heparin-Induced Thrombocytopenia Topic Discussion
Heparin-Induced Thrombocytopenia (HIT) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Figure taken from Uptodate (see references
Type 2 HIT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis of HIT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pretest Probability of HIT The 4 T’s ,[object Object],[object Object],[object Object],[object Object]
The 4 T’s  Thrombocytopenia ,[object Object],[object Object],[object Object]
The 4 T’s  Timing of platelet count fall ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The 4 T’s  Thrombosis or other sequelae ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The 4 T’s Other causes for thrombocytopenia present ,[object Object],[object Object],[object Object]
The 4 T’s Score ,[object Object],[object Object],[object Object]
Clinical Presentation ,[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Lepirudin (Refludan®) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bivalirudin (Angiomax®) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Argatroban ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fondaparinux (Arixtra®) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Back to the case… ,[object Object],[object Object],[object Object],[object Object]
Back to the case… ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Back to the case… ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
St. Luke’s Policy
 
References ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Anticoagulation in hemodialysis
Anticoagulation in hemodialysisAnticoagulation in hemodialysis
Anticoagulation in hemodialysis
Vishal Ramteke
 
Anticoagulant Reversal
Anticoagulant ReversalAnticoagulant Reversal
Anticoagulant Reversal
derosaMSKCC
 

Was ist angesagt? (20)

Heparin induced thrombocytopenia hit
Heparin induced thrombocytopenia hitHeparin induced thrombocytopenia hit
Heparin induced thrombocytopenia hit
 
Induction agents in renal transplantation
Induction agents in renal transplantationInduction agents in renal transplantation
Induction agents in renal transplantation
 
Hemodialysis anticoagulation
Hemodialysis anticoagulationHemodialysis anticoagulation
Hemodialysis anticoagulation
 
HITT
HITTHITT
HITT
 
Extracorporeal therapies for toxin ingestion by Dr Darren Roberts
Extracorporeal therapies for toxin ingestion by Dr Darren Roberts			Extracorporeal therapies for toxin ingestion by Dr Darren Roberts
Extracorporeal therapies for toxin ingestion by Dr Darren Roberts
 
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr....
 
Anticoagulation
AnticoagulationAnticoagulation
Anticoagulation
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Anticoagulation in hemodialysis
Anticoagulation in hemodialysisAnticoagulation in hemodialysis
Anticoagulation in hemodialysis
 
Heparin Induced Thrombocytopeia (HIT)
Heparin Induced Thrombocytopeia (HIT)Heparin Induced Thrombocytopeia (HIT)
Heparin Induced Thrombocytopeia (HIT)
 
NOACS.Newer Anticoagulant.
NOACS.Newer Anticoagulant.NOACS.Newer Anticoagulant.
NOACS.Newer Anticoagulant.
 
Diuretic resistence
Diuretic resistenceDiuretic resistence
Diuretic resistence
 
ABOi Kidney Transplant
ABOi Kidney TransplantABOi Kidney Transplant
ABOi Kidney Transplant
 
Diuretic resistance
Diuretic resistanceDiuretic resistance
Diuretic resistance
 
Anticoagulant Reversal
Anticoagulant ReversalAnticoagulant Reversal
Anticoagulant Reversal
 
SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
 
Basics of immunosuppression in kidney transplantation
Basics of immunosuppression in kidney transplantationBasics of immunosuppression in kidney transplantation
Basics of immunosuppression in kidney transplantation
 
New oral anticoagulant shivaomfinal noac
New oral anticoagulant shivaomfinal noacNew oral anticoagulant shivaomfinal noac
New oral anticoagulant shivaomfinal noac
 
Managment of thrombocytopenia in ICU..pptx
Managment of thrombocytopenia in ICU..pptxManagment of thrombocytopenia in ICU..pptx
Managment of thrombocytopenia in ICU..pptx
 
Bivalirudin
BivalirudinBivalirudin
Bivalirudin
 

Andere mochten auch

att4_Rice_Sep07
att4_Rice_Sep07att4_Rice_Sep07
att4_Rice_Sep07
pharmdude
 
Thrombophilia by mohamed ramadan
Thrombophilia by mohamed ramadanThrombophilia by mohamed ramadan
Thrombophilia by mohamed ramadan
Mohamed Ramadan
 
Antiphospholipid Antibody syndrome- Updated Guidelines
Antiphospholipid Antibody syndrome- Updated GuidelinesAntiphospholipid Antibody syndrome- Updated Guidelines
Antiphospholipid Antibody syndrome- Updated Guidelines
Suneth Weerarathna
 
4 Critical Care Case Study
4 Critical Care Case Study4 Critical Care Case Study
4 Critical Care Case Study
Casey Burritt
 
Anticoagulant
AnticoagulantAnticoagulant
Anticoagulant
chinoo281
 

Andere mochten auch (20)

Heparine induced thrombocytopenia
Heparine induced thrombocytopeniaHeparine induced thrombocytopenia
Heparine induced thrombocytopenia
 
Bleeding and coagulopathy
Bleeding and coagulopathyBleeding and coagulopathy
Bleeding and coagulopathy
 
Venous thromboembolisms and lovenox
Venous thromboembolisms and lovenoxVenous thromboembolisms and lovenox
Venous thromboembolisms and lovenox
 
HYPOFIBRINOLYSIS A Risk Factor for ARTERIAL THROMBOSIS AND VENOUS THROMBOSIS
HYPOFIBRINOLYSIS A Risk Factor for ARTERIAL THROMBOSIS AND VENOUS THROMBOSISHYPOFIBRINOLYSIS A Risk Factor for ARTERIAL THROMBOSIS AND VENOUS THROMBOSIS
HYPOFIBRINOLYSIS A Risk Factor for ARTERIAL THROMBOSIS AND VENOUS THROMBOSIS
 
att4_Rice_Sep07
att4_Rice_Sep07att4_Rice_Sep07
att4_Rice_Sep07
 
Deep vein thrombosis
Deep vein thrombosisDeep vein thrombosis
Deep vein thrombosis
 
BIOTECHNOLOGICAL APPLICATIONS 1
BIOTECHNOLOGICAL APPLICATIONS 1BIOTECHNOLOGICAL APPLICATIONS 1
BIOTECHNOLOGICAL APPLICATIONS 1
 
Reccurent Pregnancy Loss
Reccurent Pregnancy LossReccurent Pregnancy Loss
Reccurent Pregnancy Loss
 
Thrombophilia by mohamed ramadan
Thrombophilia by mohamed ramadanThrombophilia by mohamed ramadan
Thrombophilia by mohamed ramadan
 
Thrombophilia
ThrombophiliaThrombophilia
Thrombophilia
 
Antiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx newAntiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx new
 
Case Presentation 1 ICU
Case Presentation 1 ICUCase Presentation 1 ICU
Case Presentation 1 ICU
 
A Case of Antiphospholipid Antibody Syndrome
A Case of Antiphospholipid Antibody SyndromeA Case of Antiphospholipid Antibody Syndrome
A Case of Antiphospholipid Antibody Syndrome
 
Pseudovasculitides. Mikhail Valivach. 2015
Pseudovasculitides. Mikhail Valivach. 2015Pseudovasculitides. Mikhail Valivach. 2015
Pseudovasculitides. Mikhail Valivach. 2015
 
Thrombophilias
ThrombophiliasThrombophilias
Thrombophilias
 
Enoxaparin
EnoxaparinEnoxaparin
Enoxaparin
 
Antiphospholipid Antibody syndrome- Updated Guidelines
Antiphospholipid Antibody syndrome- Updated GuidelinesAntiphospholipid Antibody syndrome- Updated Guidelines
Antiphospholipid Antibody syndrome- Updated Guidelines
 
4 Critical Care Case Study
4 Critical Care Case Study4 Critical Care Case Study
4 Critical Care Case Study
 
New Diagnostics Guiding Oncology Treatment Decisions
New Diagnostics Guiding Oncology Treatment DecisionsNew Diagnostics Guiding Oncology Treatment Decisions
New Diagnostics Guiding Oncology Treatment Decisions
 
Anticoagulant
AnticoagulantAnticoagulant
Anticoagulant
 

Ähnlich wie Heparin Induced Thrombocytopenia Handout

Perioperative Optimisation of Coagulation and Haemostasis
Perioperative Optimisation of Coagulation and HaemostasisPerioperative Optimisation of Coagulation and Haemostasis
Perioperative Optimisation of Coagulation and Haemostasis
Andrew Ferguson
 
Ms2010 potpourri
Ms2010 potpourriMs2010 potpourri
Ms2010 potpourri
bumccon
 
VTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptx
VTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptxVTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptx
VTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptx
AbdirisaqJacda1
 

Ähnlich wie Heparin Induced Thrombocytopenia Handout (20)

Approach to thrombocytopenia
Approach to thrombocytopeniaApproach to thrombocytopenia
Approach to thrombocytopenia
 
Case study thrombocytopenia
Case study thrombocytopeniaCase study thrombocytopenia
Case study thrombocytopenia
 
Perioperative Optimisation of Coagulation and Haemostasis
Perioperative Optimisation of Coagulation and HaemostasisPerioperative Optimisation of Coagulation and Haemostasis
Perioperative Optimisation of Coagulation and Haemostasis
 
Itp
ItpItp
Itp
 
Septic shock
Septic shockSeptic shock
Septic shock
 
Ms2010 potpourri
Ms2010 potpourriMs2010 potpourri
Ms2010 potpourri
 
VTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptx
VTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptxVTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptx
VTE Seminar ,,,,,,,,,,,,,,,.....................(2).pptx
 
Review on management of Dengue.pptx
Review on management of Dengue.pptxReview on management of Dengue.pptx
Review on management of Dengue.pptx
 
Venous Thromboembolism
Venous ThromboembolismVenous Thromboembolism
Venous Thromboembolism
 
Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism
 
Presentation
PresentationPresentation
Presentation
 
Mr 2.24.14
Mr 2.24.14Mr 2.24.14
Mr 2.24.14
 
Pediatric Venous Thromboembolism 2012
Pediatric Venous Thromboembolism 2012Pediatric Venous Thromboembolism 2012
Pediatric Venous Thromboembolism 2012
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
 
Recent advances in antithrombotics
Recent advances in antithromboticsRecent advances in antithrombotics
Recent advances in antithrombotics
 
A Case of Warfarin induced SDH
A Case of Warfarin induced SDHA Case of Warfarin induced SDH
A Case of Warfarin induced SDH
 
Acquired hemophilia a
Acquired hemophilia aAcquired hemophilia a
Acquired hemophilia a
 
Medicine 5th year, 11th lecture/part one (Dr. Sabir)
Medicine 5th year, 11th lecture/part one (Dr. Sabir)Medicine 5th year, 11th lecture/part one (Dr. Sabir)
Medicine 5th year, 11th lecture/part one (Dr. Sabir)
 
What is New in ITP
What is New in ITPWhat is New in ITP
What is New in ITP
 
Antithrombotic drugs
Antithrombotic drugsAntithrombotic drugs
Antithrombotic drugs
 

Heparin Induced Thrombocytopenia Handout

Hinweis der Redaktion

  1. Patient has had approximately 2 previous hospital visits in 2010 -pneumonia -acute hypoglycemic episodes BNP-possible CHF/fluid overload Bipap-bi level positive airway pressure
  2. Phyontadione-vitamin K
  3. Note the drop from 138 which was her baseline
  4. PF4-heparin neutralizing protein released by activated platelets Type I is Non immune mediated not associated with increased risk of thrombosis Up to 8% of patients will develop the antibody associated with HIT. 1-5% of patients on heparin will develop HIT with thrombocytopenia
  5. Thrombotic complications develop in 20-50% of pts
  6. HIT is difficult to diagnose because medical and surgical pts may have multiple causes for thrombocytopenia
  7. A score is determined for each category. Scores can range from 0 to 8
  8. Nadir=low point
  9. Platelets rise 2-3 days after discontinuing heparin and return to normal with 4 to 10 days Antibodies disappear 2-3 months after cessation of therapy Atypical manifestations:heparin-induced skin necrosis, venous gangrene of limbs, anaphylactic-type reactions
  10. Including heparin-bonded catheters, heparin flushes and LMWH should be avoided due to cross reactivity Which ones for reduced renal function? Argatroban at standard doses or lepirudin at reduced doses
  11. First monitor aPTT 4 hours after start of infusion. Draw aPTT at least once daily during treatment—more if renal or hepatic impairment Dose adjustment based on crcl
  12. Dose reduction based on crcl. Okay for hepatic impairment. Monitor activated clotting time
  13. Monitor aPTT after 2 hours---adjust dose to get goal aPTT Do not exceed 100 seconds Metabolized by the liver—dose adjust in severe hepatic impairment dose of 0.5 mcg/kg/min
  14. Is indicated for DVT in conjunction with
  15. More like type 1, although presence of antibodies is confusing